ExoStat Medical has completed an intensive care unit (ICU) observational septic shock study of its MicroTREND System.
The study focused on the use of oral mucosal partial pressure CO₂ (PₒₘCO₂) as a parameter for assessing microcirculatory tissue perfusion.
Go deeper with GlobalData
It involved the data generated by MicroTREND, a Food and Drug Administration (FDA)-cleared non-invasive monitoring system, which identifies PₒₘCO₂ through a microsensor placed on the buccal tissue inside the cheek.
This method does not involve the use of needles, blood draws, catheters, or the waiting period typically associated with laboratory work.
Carried out at the Second Affiliated Hospital of Anhui Medical University in China, the study involved 23 septic shock subjects and evaluated the role of bedside oral mucosa tissue monitoring PₒₘCO₂ as an indicator of early septic shock dysfunction.
According to the findings, data produced by MicroTREND as an adjunct tool could improve the value of data collected by the macrohaemodynamic tools, which are part of the standard protocol in treating septic shock.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe study has concluded the comparative analysis of current standards of care, including serum lactate.
Its principal investigators are preparing to publish the results soon.
ExoStat senior technology and medical adviser Wanchun Tang said: “This first-ever study marks a major milestone for critical care, for ExoStat, and for me as it has been a 40-year project that started with the Weil Institute in the 1980s.
“This device can produce actuals that can provide the physician with more reaction time. It is now well-understood that the current macrohaemodynamic tools do not fully capture real-time metrics of the patient under care. This study finally brought what was a hypothesis into reality. It was exciting to observe.”
